Optimal prognostic and predictive biomarkers for patients with advanced-stage cancer patients who received immunotherapy (IO) are lacking. Inflammatory markers, such as the neutrophil-to-lymphocyte ratio (NLR), the monocyte-to-lymphocyte ratio (MLR), and the platelet-to-lymphocyte ratio (PLR), are readily available. The authors investigated the association between these markers and clinical outcomes of patients with advanced-stage cancer who received IO. METHODS: A retrospective review was conducted of 90 patients with advanced cancer who received treatment on phase 1 clinical trials of IO-based treatment regimens. NLR, MLR, and PLR values were log-transformed and treated as continuous variables for each patient. Overall survival (OS), progression-free survival (PFS), and clinical benefit were used to measure clinical outcomes. For univariate associations and multivariable analyses, Cox proportional-hazards models or logistic regression models were used. RESULTS: The median patient age was 63 years, and most were men (59%). The most common histologies were melanoma (33%) and gastrointestinal cancers (22%). High baseline NLR, MLR, and PLR values were associated significantly with worse OS and PFS (P < .05) and a lower chance of benefit (NLR and PLR; P < .05). Increased NLR, MLR, and PLR values 6 weeks after baseline were associated with shorter OS and PFS (P ≤ .052). CONCLUSIONS: Baseline and early changes in NLR, MLR, and PLR values were strongly associated with clinical outcomes in patients who received IO-based treatment regimens on phase 1 trials. Confirmation in a homogenous patient population treated on late-stage trials or outside of trial settings is warranted. These values may warrant consideration for inclusion when risk stratifying patients enrolled onto phase 1 clinical trials of IO agents. Cancer 2019;125:127-134.
INTRODUCTION
Immunotherapy (IO) has emerged as a treatment option for patients with a variety of malignancies because of the potential for durable clinical benefit and favorable toxicity profile. 1, 2 In total, 6 IO agents targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (ipilimumab), programmed cell death 1 (PD-1) (nivolumab and pembrolizumab), or programmed cell death ligand 1 (PD-L1) (atezolizumab, avelumab, and durvalumab) gained US Food and Drug Administration approval as of January 2018. 3 There are several other IO agents currently under development. 4 Given the increased use of IO in clinics, as well as an encouraging but limited response population, identifying biomarkers of response to these agents represents a critical area of research. Recent studies have implicated angiopoietin-2 as well as polybromo-1 (PBRM1) and polybromo-associated barrier-to-autointegration factor (PBAF) as biomarkers of response to IO in melanoma and renal cell carcinoma (RCC), respectively. 5, 6 PD-L1 expression has been associated with response to pembrolizumab in lung cancer, but the associations between this biomarker and other cancers and agents in the class are less reliable. [7] [8] [9] Data on other biomarkers of response and toxicity to IO are lacking.
Inflammation has been described as 1 hallmark of cancer. 10 Neutrophils play an important role in inflammation as effectors of both innate immunity and cell signaling in the adaptive immune response. 11, 12 They also inhibit the activity of cytotoxic T lymphocytes in vitro. 13 Monocytes contribute to the inflammatory process through their patterns of differentiation into macrophages or dendritic cells in the tissue microenvironment. 14 Platelets also have an active role in inflammation by releasing vascular endothelial growth factor (VEGF), which mediates the migration and extravasation of leukocytes, and platelet-derived growth factor (PDGF), a chemokine that recruits neutrophils and monocytes. 15 Furthermore, the presence of T lymphocytes in the tumor microenvironment is associated with improved outcomes in several malignancies. 16 Given these processes, the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) have been used as markers of systemic inflammation and are associated with poor outcomes in several malignancies. [17] [18] [19] In the current study, we are investigating the potential association of NLR, PLR, and MLR with clinical outcomes across a wide variety of malignancies treated with IO.
MATERIALS AND METHODS

Patients and Data
We reviewed clinical data from 90 patients with advanced cancer who received treatment on IO-based phase 1 clinical trials at the Winship Cancer Institute of Emory University between 2009 and 2017. Data collected from the patient's electronic medical record included: demographic information, medication allergies, histology, Eastern Cooperative Oncology Group (ECOG) performance status, number and site of distant metastases, number and type of prior lines of systemic therapy, prior exposure to IO, best response to IO on trial, date of radiographic or clinical progression, immune-related adverse events, date of death or last follow-up, and Royal Marsden Hospital (RMH) risk factors (albumin <3.5 g/ dL, lactate dehydrogenase greater than the upper limit of normal, and >2 sites of metastasis). Hemoglobin, NLR, MLR, and PLR values were collected at baseline and at 6 ± 2 weeks after therapy initiation. Response to treatment was determined by using Response Evaluation Criteria in Solid Tumor, version 1.1, by centralized review.
Statistical Analysis
Clinical endpoints were defined as overall survival (OS) (months from IO initiation to death or loss to follow-up with transition of care to hospice), progression-free survival (PFS) (months from IO initiation to radiographic or clinical progression/death/hospice), and clinical benefit (CB) (sum of objective responses as complete response, partial response, and stable disease). Clinical progression was defined as a patient coming off trial for declining performance status. NLR, MLR, and PLR values were logtransformed and treated as continuous variables.
Statistical analysis was conducted using SAS version 9.4 (SAS Institute, Inc, Cary, NC), and SAS macros developed by the Biostatistics and Bioinformatics Shared Resource at Winship Cancer Institute. 20 The significance level was set at P < .05. Descriptive statistics for each variable were reported. The statistical modeling with OS or PFS was conducted using a proportional-hazards model and logistic regression for CB. All multivariable models were built by backward elimination steps with an α level of .2 for removal. The nonlinear relation between each log-transformed biomarker and OS or PFS was examined using the martingale residual plot, and an optimal cutoff value of the biomarkers was determined by a bias-adjusted log-rank test after searching all possible cuts in terms of OS. 21 In the second part of the analysis, we examined whether the change of these biomarkers 6 ± 2 weeks after treatment initiation could predict clinical outcomes. This time point was chosen because it should coincide with the first restaging scans on trial. Patients who remained event-free within 7 weeks after IO were included in this part of the analysis, which left 79 patients for OS analysis and 61 patients for PFS analysis.
RESULTS
Summary of Baseline Information
Patient demographic information and disease characteristics are presented in Table 1 . The majority of patients (58.9%) were men. The most common histologies were melanoma (33.3%), gastrointestinal cancers (22.2%), and lung or head and neck cancers (20.0%). Most patients (68.9%) had received at least 2 prior lines of systemic treatment, and 27 patients (30.0%) had prior exposure to IO. Only 17 patients (19.3%) were in the RMH poor-risk group at the start of IO. The treatment Cancer January 1, 2019 regimen breakdown was as follows: 27.8% (n = 25) of patients received PD-L1 monotherapy, 51.1% (n = 46) received a US Food and Drug Administration-approved IO agent combined with an experimental IO agent, and 21.1% (n = 19) received an experimental IO agent as monotherapy.
Association of Baseline Blood-Based Biomarkers and Clinical Outcomes
The association between baseline blood-based biomarkers and clinical outcomes is detailed in Table 2 Fig. 1 ). The multivariate analysis controlled for age, prior IO, number of prior therapies, RMH risk group, number of metastatic sites, and the presence of liver metastases at the start of IO. Median OS and 12-month OS were longer for patients who had low NLR, MLR, and PLR values at baseline (Table 3 ). Figure 1A -C provides Kaplan-Meier curves illustrating the association of NLR, MLR, and PLR values with OS at baseline. Cancer January 1, 2019
Association of Change in Blood-Based Biomarkers With Clinical Outcomes
The associations between changes in NLR, MLR, and PLR values at 6 ± 2 weeks after therapy initiation and OS and PFS are detailed in Table 2 . An increase in NLR and MLR at 6 weeks from baseline were both significantly associated with shorter OS (NLR: HR, 4.11; 95% CI, 1.86-9.11; P < .001; MLR: HR, 2.26; 95% CI, 1.06-4.79; P = .034) and PFS (NLR: HR, 2.58; 95% CI, 1.38-4.80; P = .003; MLR: HR, 2.02; 95% CI, 1.09-3.74; P = .026). An increased PLR was significantly associated with worse OS (HR, 3.13; 95% CI, 1.42-6.88; P = .005) and trended toward shorter PFS (HR, 1.84; 95% CI, 0.99-3.41; P = .052). The median OS for patients who had an increase in log-transformed NLR, MLR, and PLR values at 6 ± 2 weeks was considerably shorter than that for patients who had a decrease (Table 3) . Kaplan-Meier plots for the association between a change in each variable and OS are provided in Figure 2A -C.
DISCUSSION
In the current study, we demonstrated that elevated baseline and early increases in NLR, MLR, and PLR values were associated with worse clinical outcomes in patients with advanced-stage cancer who received IObased treatment on phase 1 clinical trials. The results of this retrospective analysis support previous data on the association between these biomarkers and clinical outcomes in patients who received IO. [22] [23] [24] [25] Although previous studies have investigated the role of NLR and PLR on clinical outcomes in patients who received IO, to our knowledge, this is the first study to incorporate MLR in an analysis of patients with a wide variety of malignancies who received IO. Our study is also unique in that the prognostic and predictive values of these 3 variables were demonstrated in patients who were received novel IO combinations.
The current findings are of clinical importance given the need for patient selection, because only a minority of patients benefit from IO. Moreover, because these biomarkers are readily available as part of the routine, standard management of patients with cancer, application in the real-world setting would be easy if it were prospectively validated. Radiographic assessment of treatment responses can be heterogeneous in patients who receive IO. 26 Changes in the values of these blood-based biomarkers around the time of the first set of restaging scans may further assist in clarifying patient status for situations in which the radiologic findings are inconclusive. These values would provide adjunctive data points on which to base the decision regarding whether the patient is deriving CB from treatment. The real-world value of NLR, MLR, and PLR was demonstrated by 2 patients included in this analysis who achieved a best response of stable disease on their first restaging scan. One of these patients had an increase in NLR, MLR, and PLR at the time of the initial restaging scan and experienced progressive disease at the second restaging scan. Conversely, the other patient had a decrease in NLR, MLR, and PLR at 6 weeks and later achieved a partial response on subsequent tumor assessment.
The results from this study may have an impact on the risk stratification of patients enrolled onto later phase efficacy clinical trials. Similar to other validated prognostic scores used to assess patient suitability for phase 1 trials, such as the RMH score, the Hammersmith score, the Princes Margaret Hospital Index, and the Nijmegen score (which have been effective at predicting survival differences between high-risk and low-risk groups), we believe that NLR, MLR, or PLR could provide a more relevant patient-selection factor in this era of cancer IO. 3, [27] [28] [29] The effectiveness of these markers of inflammation in prognostication of survival is well established across numerous malignancies in various settings. One potential explanation for the impact of these markers is that an increase in NLR, MLR, and PLR values on Abbreviations: CI, confidence interval; MLR, monocyte-to-lymphocyte ratio; NA, not applicable; NLR, neutrophil-to-lymphocyte ratio; OC, optimal cutoff; PLR, platelet-to-lymphocyte ratio.
Cancer January 1, 2019 Figure 2 . Kaplan-Meier plots illustrate changes in (A) the neutrophil-to-lymphocyte ratio (NLR), (B) the monocyte-to-lymphocyte ratio (MLR), and (C) the platelet-to-lymphocyte ratio (PLR) and their association with overall survival (OS). OC indicates optimal cutoff.
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treatment may indicate a nonspecific reaction and a failure to expand the lymphocyte compartment. Inclusion of these markers of inflammation in updated prognostic models may optimize the stratification of patients who are enrolled on phase 1 clinical trials regardless of the type of IO they receive. Although the current study presents clinically relevant data, there are several limitations that should be mentioned. First, the patient population is heterogeneous. We included all patients enrolled onto these trials regardless of their histology or the type of IO they received. However, our multivariate analysis was still significant when we included histology type. This was also a retrospective study and thus is inherently subject to selection bias, but we included all patients regardless of the trial's inclusion criteria or the type of IO agent used in the trial. We also controlled for this by including many covariates that reflected disease characteristics and prior treatment information that may have confounded the results of our analysis. Moreover, this was a qualitative correlative analysis without mechanistic studies to further elucidate why these biomarkers were correlated with outcome on IO therapy. Finally, this was a single-center study without an external validation cohort, which limits generalizability of the study results. Future studies that analyze baseline and on-study tissue samples may shed light on the biologic explanation for the prognostic and predictive values of NLR, MLR, and PLR.
CONCLUSION
Elevated baseline and early increases in NLR, MLR, and PLR values are strongly associated with poor clinical outcomes in this cohort of patients treated on IO-based phase 1 clinical trials. These values may warrant consideration when risk-stratifying patients who are being enrolled onto phase 1 clinical trials. Given the high concordance among these variables, any of these markers may be used in future analysis. Future studies investigating the relation between changes in these values and the tumor microenvironment are crucial to elucidate the underlying biologic explanation for the prognostic and predictive value of these markers.
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